1. Aguilar-Roblero R, Drucker-Colin R, Moore RY. Behavioral and morphological studies of fetal neural transplants into SCN-lesioned rats. Chronobiol Int 1992;9:278-296.

2. Albers HE, Liou SY, Stopa EG, Zoeller RT. Interaction of colocalized neuropeptides: functional significance in the circadian timing system. J Neurosci 1991;11:846-851.

3. Alexander LD, Sander LD. Involvement of vasopressin and corticotropin-releasing hormone in VIP- and PHI-induced secretion of ACTH and corticosterone. Neuropeptides 1995;28:167-173.

4. Baldino F, Jr., Fitzpatrick-McElligott S, Gozes I, Card JP. Localization of VIP and PHI-27 messenger RNA in rat thalamic and cortical neurons. J Mol Neurosci 1989;1:199-207.

5. Baldwin C, Sasek CA, Zigmond RE. Evidence that some preganglionic sympathetic neurons in the rat contain vasoactive intestinal peptide- or peptide histidine isoleucine amide-like immunoreactivities. Neuroscience 1991;40:175-184.

6. Balsa JA, Sanchez-Franco F, Lorenzo MJ, Pazos F, Lara JI, Cacicedo L. Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion. Endocrinology 1996;137:508-513.

7. Besson J, Sarrieau A, Vial M, Marie JC, Rosselin G, Rostene W. Characterization and autoradiographic distribution of vasoactive intestinal peptide binding sites in the rat central nervous system. Brain Res 1986;398:329-336.

8. Bleuel A, de Gasparo M, Whitebread S, Puttner I, Monard D. Regulation of protease nexin-1 expression in cultured Schwann cells is mediated by angiotensin II receptors. J Neurosci 1995;15:750-761.

9. Bodner M, Fridkin M, Gozes I. Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome. Proc Natl Acad Sci USA 1985;82:3548-3551.

10. Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 1995;37:57-66.

11. Bosler O, Jacomy H, Boulaich S, et al. Vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and related regulatory peptides: from molecular biology to clinical applications. In: The VIP neuronal system of the suprachiasmatic nucleus of the hypothalamus, with special reference to afferent and efferent synaptic connectivity. Rosselin G, ed. Singapore: World Scientific, 1994;272-282.

12. Botchkina GI, Morin LP. Ontogeny of radial glia, astrocytes and vasoactive intestinal peptide immunoreactive neurons in hamster suprachiasmatic nucleus. Brain Res Dev Brain Res 1995;86:48-56.

13. Brenneman DE, Eiden LE. Vasoactive intestinal peptide and electrical activity influence neuronal survival. Proc Natl Acad Sci USA 1986;83:1159-1162.

14. Brenneman DE, Foster GA. Structural specificity of peptides influencing neuronal survival during development. Peptides 1987;8:687-694.

15. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide [see comments]. J Clin Invest 1996;97:2299-2307.

16. Brenneman DE, Hill JM, Glazner GW, Gozes I, Phillips TW. Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival. Int J Dev Neurosci 1995;13:187-200.

17. Brenneman DE, McCune SK, Gozes I. Acquired immune deficiency syndrome and the developing nervous system. Int Rev Neurobiol 1990;32: 305-353.

18. Brenneman DE, Neale EA, Foster GA, d'Autremont SW, Westbrook GL. Nonneuronal cells mediate neurotrophic action of vasoactive intestinal peptide. J Cell Biol 1987;104:1603-1610.

19. Brenneman DE, Nicol T, Warren D, Bowers LM. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J Neurosci Res 1990;25:386-394.

20. Brenneman DE, Schultzberg M, Bartfai T, Gozes I. Cytokine regulation of neuronal survival. J Neurochem 1992;58:454-460.

21. Brenneman DE, Westbrook GL, Fitzgerald SP, et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988;335:639-642.

22. Burgunder JM. Chemical neuro-anatomy of the thalamus: an example of the co-expression of 2 neuropeptides, cholecystokinin and intestinal vasoactive peptide. Schweiz Med Wochenschr 1990;120:1180-1185.

23. Cardinaux JR, Magistretti PJ. Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism. J Neurosci 1996;16:919-929.

24. Cavallaro S, Copani A, D'Agata V, et al.. Pituitary adenylate cyclase activating polypeptide prevents apoptosis in cultured cerebellar granule neurons. Mol Pharmacol 1996;50:60-66.

25. Cavanagh ME, Parnavelas JG. Development of vasoactive-intestinal-polypeptide-immunoreactive neurons in the rat occipital cortex: a combined immunohistochemical-autoradiographic study. J Comp Neurol 1989;284:637-645.

26. Ceccatelli S, Fahrenkrug J, Villar MJ, Hokfelt T. Vasoactive intestinal polypeptide/peptide histidine isoleucine immunoreactive neuron systems in the basal hypothalamus of the rat with special reference to the portal vasculature: an immunohistochemical and in situ hybridization study. Neuroscience 1991;43:483-502.

27. Charnay Y, Chayvialle JA, Said SI, Dubois PM. Localization of vasoactive intestinal peptide immunoreactivity in human foetus and newborn infant spinal cord. Neuroscience 1985;14:195-205.

28. Chelbi-Alix MK, Brouard A, Boissard C, Pelaprat D, Rostene W, Thang MN. Induction by vasoactive intestinal peptide of interferon alpha/beta synthesis in glial cells but not in neurons. J Cell Physiol 1994;158:47-54.

29. Chew LJ, Murphy D, Carter DA. Alternatively polyadenylated vasoactive intestinal peptide mRNAs are differentially regulated at the level of stability. Mol Endocrinol 1994;8:603-613.

30. Chew LJ, Pardy K, Murphy D, Carter DA. Osmotic stimuli attenuate vasoactive intestinal peptide gene expression in the rat anterior pituitary gland. Mol Cell Endocrinol 1993;92:9-14.

31. Chik CL, Young I, Ho AK. Differential involvement of the arachidonic acid cascade on the alpha 1-adrenergic potentiation of vasoactive intestinal peptide-versus beta-adrenergic-stimulated cyclic AMP and cyclic GMP accumulation in rat pinealocytes. J Neurochem 1991;57:1534-1539.

32. Chneiweiss H, Glowinski J, Premont J. Vasoactive intestinal polypeptide receptors linked to an adenylate cyclase, and their relationship with biogenic amine-and somatostatin-sensitive adenylate cyclases on central neuronal and glial cells in primary cultures. J Neurochem 1985;44:779-786.

33. Cottrell GA, Veldhuis HD, Rostene WH, de Kloet ER. Behavioral actions of vasoactive intestinal peptide (VIP). Neuropeptides 1984;4:331-341.

34. Dauphin F, MacKenzie ET. Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries. Pharmacol Ther 1995;67:385-417.

35. Davidson A, Moody TW, and Gozes I. Regulation of VIP gene expression in general: human lung cancer cells in particular. J Mol Neurosci 1996;7:99-110.

36. Dodd J, Kelly JS, Said SI. Excitation of CA1 neurones of the rat hippocampus by the octacosapeptide, vasoactive intestinal polypeptide (VIP) [proceedings]. Br J Pharmacol 1979;66:125P.

37. Duvilanski BH, Lasaga M, Seilicovich A, Afione S, Diaz MC, Debeljuk L. Vasoactive intestinal peptide affects the GABAergic system in the hypothalamic-pituitary axis. Brain Res Bull 1990;25:215-219.

38. el Kafi B, Cespuglio R, Leger L, Marinesco S, Jouvet M. Is the nucleus raphe dorsalis a target for the peptides possessing hypnogenic properties? Brain Res 1994;637:211-221.

39. el Kafi B, Leger L, Seguin S, Jouvet M, Cespuglio R. Sleep permissive components within the dorsal raphe nucleus in the rat. Brain Res 1995;686:150-159.

40. Emson PC, Gilbert RF, Loren I, Fahrenkrug J, Sundler F, Schaffalitzky de Muckadell OB. Development of vasoactive intestinal polypeptide (VIP) containing neurones in the rat brain. Brain Res 1979;177:437-444.

41. Evans PD, Villegas J. The action of vasoactive intestinal peptide antagonists on peptidergic modulation of the squid Schwann cell. J Exp Biol 1988;138:259-269.

42. Fatatis A, Holtzclaw LA, Avidor R, Brenneman DE, Russell JT. Vasoactive intestinal peptide increases intracellular calcium in astroglia: synergism with alpha-adrenergic receptors. Proc Natl Acad Sci USA 1994;91:2036-2040.

43. Festoff BW, Nelson JB, and Brenneman DE. Prevention of activity-dependent neuronal death: vasoactive intestinal polypeptide stimulates astrocytes to secrete the thrombin-inhibiting neurotrophic serpin, protease nexin-1. J Neurobiol 1996;30:255-266.

44. Fink JS, Verhave M, Walton K, Mandel G, Goodman RH. Cyclic AMP- and phorbol ester-induced transcriptional activation are mediated by the same enhancer element in the human vasoactive intestinal peptide gene. J Biol Chem 1991;266:3882-3887.

45. Flood JF, Garland JS, Morley JE. Vasoactive intestinal peptide (VIP): an amnestic neuropeptide. Peptides 1990;11:933-938.

46. Georg B, Wulff BS, Fahrenkrug J. Characterization of the effects of retinoic acid on vasoactive intestinal polypeptide gene expression in neuroblastoma cells. Endocrinology 1994;135:1455-1463.

47. Giladi E, Shani Y, Gozes I. The complete structure of the rat VIP gene. Brain Res Mol Brain Res 1990;7:261-267.

48. Glazer R, Gozes I. Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining. Brain Res 1994;644:164-167.

49. Glowa JR, Panlilio LV, Brenneman DE, Gozes I, Fridkin M, Hill JM. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res 1992;570:49-53.

50. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994;117:427-434.

51. Gottschall PE, Tatsuno I, Arimura A. Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res 1994;637:197-203.

52. Gozes I, Avidor R, Giladi E, et al. Adrenalectomy decreases vasoactive intestinal peptide mRNA levels in the rat suprachiasmatic nucleus. Neurosci Lett 1994;167:24-28.

53. Gozes I, Avidor R, Yahav Y, Katznelson D, Croce CM, Huebner K. The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21–-6qter. Hum Genet 1987;75:41-44.

54. Gozes I, Bardea A, Reshef A, et al. Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide. Proc Natl Acad Sci USA 1996;93:427-432.

55. Gozes I, Brenneman DE. VIP: molecular biology and neurobiological function. Mol Neurobiol 1989;3:201-236.

56. Gozes I, Fridkin M, Brenneman DE. A VIP hybrid antagonist: from developmental neurobiology to clinical applications. Cell Mol Neurobiol 1995;15:675-687.

57. Gozes I, Glowa J, Brenneman DE, McCune SK, Lee E, Westphal H. Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene. J Mol Neurosci 1993;4:185-193.

58. Gozes I, Lilling G, Glazer R, et al. Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 1995;273:161-167.

59. Gozes I, McCune SK, Jacobson L, et al. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J Pharmacol Exp Ther 1991;257:959-966.

60. Gozes I, Schachter P, Shani Y, Giladi E. Vasoactive intestinal peptide gene expression from embryos to aging rats. Neuroendocrinology 1988;47:27-31.

61. Gozes I, Shani Y, Rostene WH. Developmental expression of the VIP-gene in brain and intestine. Brain Res 1987;388:137-148.

62. Gressens P, Hill JM, Gozes I, Fridkin M, Brenneman DE. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 1993;362:155-158.

63. Gressens P, Hill JM, Paindaveine B, Gozes I, Fridkin M, Brenneman DE. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J Clin Invest 1994;94:2020-2027.

64. Gulyas AI, Hajos N, Freund TF. Interneurons containing calretinin are specialized to control other interneurons in the rat hippocampus. J Neurosci 1996;16:3397-3411.

65. Hahm SH, Eiden LE. Tissue specific expression of the vasoactive intestinal peptide gene requires both an upstream tissue specific element and a 5' proximal cyclic AMP-responsive element. J Neurochem 1996;67:1872-1881.

66. Harada Y, Okubo M, Yaga K, Kaneko T, Kaku K. Neuropeptide Y inhibits beta-adrenergic agonist- and vasoactive intestinal peptide-induced cyclic AMP accumulation in rat pinealocytes through pertussis toxin-sensitive G protein. J Neurochem 1992;59:2178-2183.

67. Harmar T, Lutz E. Multiple receptors for PACAP and VIP. Trends Pharmacol Sci 1994;15:97-9.

68. Haskins JT, Samson WK, Moss RL. Evidence for vasoactive intestinal polypeptide (VIP) altering the firing rate of preoptic, septal and midbrain central gray neurons. Regul Pept 1982;3:113-123.

69. Hayashi M, Oshima K. Neuropeptides in cerebral cortex of macaque monkey (Macaca fuscata fuscata): regional distribution and ontogeny. Brain Res 1986;364:360-368.

70. Hedlund B, Dufy B, Barker L. Vasoactive intestinal polypeptide alters GH3/B6 pituitary cell excitability. Pflugers Arch 1988;411:173-179.

71. Hill JM, Agoston DV, Gressens P, McCune SK. Distribution of VIP mRNA and two distinct VIP binding sites in the developing rat brain: relation to ontogenic events. J Comp Neurol 1994;342:186-205.

72. Hill JM, Gozes I, Hill JL, Fridkin M, Brenneman DE. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 1991;12:187-192.

73. Hill JM, Harris A, Hilton-Clarke DI. Regional distribution of guanine nucleotide-sensitive and guanine nucleotide-insensitive vasoactive intestinal peptide receptors in rat brain. Neuroscience 1992;48:925-932.

74. Hill JM, McCune SK, Alvero RJ, et al. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J Clin Invest 1996;97:202-208.

75. Hill JM, Mervis RF, Politi J, et al. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann N Y Acad Sci 1994;739:211-225.

76. Hosli L, Hosli E, Heuss L, Rojas J. Electrophysiological evidence for receptors for vasoactive intestinal peptide and angiotensin II on astrocytes of cultured rat central nervous system. Neurosci Lett 1989;102:217-222.

77. Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 1992;8:811-819.

78. Jimenez-Anguiano A, Baez-Saldana A, Drucker-Colin R. Cerebrospinal fluid (CSF) extracted immediately after REM sleep deprivation prevents REM rebound and contains vasoactive intestinal peptide (VIP). Brain Res 1993;631:345-348.

79. Journot L, Waeber C, Pantaloni C, et al. Differential signal transduction by six splice variants of the pituitary adenylate cyclase-activating peptide (PACAP) receptor. Biochem Soc Trans 1995;23:133-137.

80. Kaneko T, Tashiro K, Sugimoto T, Konishi A, Mizuno N. Identification of thalamic neurons with vasoactive intestinal polypeptide-like immunoreactivity in the rat. Brain Res 1985;347:390-393.

81. Kashiba H, Senba E, Kawai Y, Ueda Y, Tohyama M. Axonal blockade induces the expression of vasoactive intestinal polypeptide and galanin in rat dorsal root ganglion neurons. Brain Res 1992;577:19-28.

82. Kasper S, Popescu RA, Torsello A, Vrontakis ME, Ikejiani C, Friesen HG. Tissue-specific regulation of vasoactive intestinal peptide messenger ribonucleic acid levels by estrogen in the rat. Endocrinology 1992;130:1796-1801.

83. Lam KS, Srivastava G, Tam SP. Divergent effects of glucocorticoid on the gene expression of vasoactive intestinal peptide in the rat cerebral cortex and pituitary. Neuroendocrinology 1992;56:32-37.

84. Lasater EM, Watling KJ, and Dowling JE. Vasoactive intestinal peptide alters membrane potential and cyclic nucleotide levels in retinal horizontal cells. Science 1983;221:1070-1072.

85. Lilling G, Wollman Y, Goldstein MN, et al. Inhibition of human neuroblastoma growth by a specific VIP antagonist. J Mol Neurosci 1994;5:231-239.

86. Loren I, Emson PC, Fahrenkrug J, et al. Distribution of vasoactive intestinal polypeptide in the rat and mouse brain. Neuroscience 1979;4:1953-1976.

87. Maggi CA, Giachetti A, Dey RD, Said SI. Neuropeptides as regulators of airway function: vasoactive intestinal peptide and the tachykinins. Physiol Rev 1995;75:277-322.

88. Magistretti PJ, Morrison JH. Noradrenaline- and vasoactive intestinal peptide-containing neuronal systems in neocortex: functional convergence with contrasting morphology. Neuroscience 1988;24:367-378.

89. Magistretti PJ, Sorg O, Yu N, Martin JL, Pellerin L. Neurotransmitters regulate energy metabolism in astrocytes: implications for the metabolic trafficking between neural cells. Dev Neurosci 1993;15:306-312.

90. McGregor GP, Woodhams PL, O'Shaughnessy DJ, Ghatei MA, Polak JM, Bloom SR. Developmental changes in bombesin, substance P, somatostatin and vasoactive intestinal polypeptide in the rat brain. Neurosci Lett 1982;28:21-27.

91. Mikkelsen JD. Immunohistochemical localization of vasoactive intestinal peptide (VIP) in the circumventricular organs of the rat. Cell Tissue Res 1989;255:307-313.

92. Moser A, Cramer H. Peptidergic modulation of G-protein coupled cyclic-AMP accumulation in the rat caudate nucleus. Neuropeptides 1992;22:143-147.

93. Mulderry PK. Neuropeptide expression by newborn and adult rat sensory neurons in culture: effects of nerve growth factor and other neurotrophic factors. Neuroscience 1994;59:673-688.

94. Muller JM, Lelievre V, Becq-Giraudon L, Meunier AC. VIP as a cell-growth and differentiation neuromodulator role in neurodevelopment. Mol Neurobiol 1995;10:115-134.

95. Nagao H, Matsuoka I, Kurihara K. Effects of adenylyl cyclase-linked neuropeptides on the expression of ciliary neurotrophic factor-mRNA in cultured astrocytes. FEBS Lett 1995;362:75-79.

96. Nicolodi M, Del Bianco E. Sensory neuropeptides (substance P, calcitonin gene-related peptide) and vasoactive intestinal polypeptide in human saliva: their pattern in migraine and cluster headache. Cephalalgia 1990;10:39-50.

97. Nowak M, Markowska A, Nussdorfer GG, Tortorella C, Malendowicz LK. Evidence that endogenous vasoactive intestinal peptide (VIP) is involved in the regulation of rat pituitary-adrenocortical function: in vivo studies with a VIP antagonist. Neuropeptides 1994;27:297-303.

98. Obal F, Jr., Payne L, Kacsoh B, et al. Involvement of prolactin in the REM sleep-promoting activity of systemic vasoactive intestinal peptide (VIP). Brain Res 1994;645:143-149.

99. Ogawa-Meguro R, Itoh K, Mizuno N. Substance P-, vasoactive intestinal polypeptide-, and cholecystokinin-like immunoreactive fiber projections from the superior colliculus to the dorsal lateral geniculate nucleus in the rat. Exp Brain Res 1992;89:59-66.

100. Ohkubo S, Kimura C, Ogi K, et al. Primary structure and characterization of the precursor to human pituitary adenylate cyclase activating polypeptide. DNA Cell Biol 1992;11:21-30.

101. Okamoto S, Okamura H, Takahashi Y, Akagi Y, Yanaihara N, Ibata Y. Contrary effect of eye enucleation on VIP-immunoreactive neurons in the suprachiasmatic nucleus and the superior colliculus of the rat. Neurosci Lett 1990;112:137-142.

102. Okamura H, Kawakami F, Tamada Y, et al. Circadian change of VIP mRNA in the rat suprachiasmatic nucleus following p-chlorophenylalanine (PCPA) treatment in constant darkness. Brain Res Mol Brain Res 1995;29:358-364.

103. Okumura N, Miyatake Y, Takao T, Tamaru T, Nagai K, Okada M, Nakagawa H. Vasoactive intestinal peptide induces differentiation and MAP kinase activation in PC12h cells. J Biochem (Tokyo) 1994;115:304-308.

104. Olah Z, Lehel C, Anderson WB, Brenneman DE, van Agoston D. Subnanomolar concentration of VIP induces the nuclear translocation of protein kinase C in neonatal rat cortical astrocytes. J Neurosci Res 1994;39:355-363.

105. Olianas MC, Onali P. Synergistic interaction of muscarinic and opioid receptors with GS-linked neurotransmitter receptors to stimulate adenylyl cyclase activity of rat olfactory bulb. J Neurochem 1993;61:2183-2190.

106. Ottesen B, Fahrenkrug J. Vasoactive intestinal polypeptide and other preprovasoactive intestinal polypeptide-derived peptides in the female and male genital tract: localization, biosynthesis, and functional and clinical significance. Am J Obstet Gynecol 1995;172:1615-1631.

107. Paul S. Decreased selectivity of vasoactive intestinal peptide receptors by GTP. Biochem Pharmacol 1989;38:699-702.

108. Pei L. Identification of a negative glucocorticoid response element in the rat type 1 vasoactive intestinal polypeptide receptor gene. J Biol Chem 1996;271:20879-20884.

109. Peters A, Harriman KM. Enigmatic bipolar cell of rat visual cortex. J Comp Neurol 1988;267:409-432.

110. Phillis JW, Kirkpatrick JR, Said SI. Vasoactive intestinal polypeptide excitation of central neurons. Can J Physiol Pharmacol 1978;56:337-340.

111. Pincus DW, DiCicco-Bloom EM, Black IB. Vasoactive intestinal peptide regulation of neuroblast mitosis and survival: role of cAMP. Brain Res 1990;514:355-357.

112. Pincus DW, DiCicco-Bloom E, Black IB. Trophic mechanisms regulate mitotic neuronal precursors: role of vasoactive intestinal peptide (VIP). Brain Res 1994;663:51-60.

113. Quik M, Iversen LL, Bloom SR. Effect of vasoactive intestinal peptide (VIP) and other peptides on cAMP accumulation in rat brain. Biochem Pharmacol 1978;27:2209-2213.

114. Rajan P, Stewart CL, Fink JS. LIF-mediated activation of STAT proteins after neuronal injury in vivo. Neuroreport 1995;6:2240-2244.

115. Rajan P, Symes AJ, Fink JS. STAT proteins are activated by ciliary neurotrophic factor in cells of central nervous system origin. J Neurosci Res 1996;43:403-411.

116. Reuss S, Decker K, Rosseler L, Layes E, Schollmayer A, Spessert R. Nitric oxide synthase in the hypothalamic suprachiasmatic nucleus of rat: evidence from histochemistry, immunohistochemistry and western blot; and colocalization with VIP. Brain Res 1995;695:257-262.

117. Roberts GW, Woodhams PL, Bryant MG, Crow TJ, Bloom SR, Polak JM. VIP in the rat brain: evidence for a major pathway linking the amygdala and hypothalamus via the stria terminalis. Histochemistry 1980;65:103-119.

118. Roky R, Obal F, Jr., Valatx JL, et al. Prolactin and rapid eye movement sleep regulation. Sleep 1995;18:536-542.

119. Rosselin G, Maletti M, Besson J, Rostene W. A new neuroregulator: the vasoactive intestinal peptide or VIP. Mol Cell Endocrinol 1982;27:243-262.

120. Rostene WH. Neurobiological and neuroendocrine functions of the vasoactive intestinal peptide (VIP). Prog Neurobiol 1984;22:103-129.

121. Said SI and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970;1691217-1218.

122. Samson WK, Said SI, Graham JW, McCann SM. Vasoactive-intestinal-polypeptide concentrations in median eminence of hypothalamus [letter]. Lancet 1978;2:901-902.

123. Schaad NC, Vanecek J, Rodriguez IR, Klein DC, Holtzclaw L, Russell JT. Vasoactive intestinal peptide elevates pinealocyte intracellular calcium concentrations by enhancing influx: evidence for involvement of a cyclic GMP-dependent mechanism. Mol Pharmacol 1995;47:923-933.

124. Schettini G, Grimaldi M, Navarra P, Pozzoli G, Reichlin S, Preziosi P. Regulation of interleukin 6 production by cAMP-protein kinase-A pathway in rat cortical astrocytes. Pharmacol Res 1994;30:13-24.

125. Sena M, Bravo DT, von Agoston D, Waschek JA. High conservation of upstream regulatory sequences on the human and mouse vasoactive intestinal peptide (VIP) genes. DNA Seq 1994;5:25-29.

126. Sessler FM, Grady SM, Waterhouse BD, Moises HC. Electrophysiological actions of VIP in rat somatosensory cortex. Peptides 1991;12:715-721.

127. Shinohara K, Honma S, Katsuno Y, Abe H, Honma K. Circadian rhythms in the release of vasoactive intestinal polypeptide and arginine-vasopressin in organotypic slice culture of rat suprachiasmatic nucleus. Neurosci Lett 1994;170:183-186.

128. Shinohara K, Honma S, Katsuno Y, Abe H, Honma K. Two distinct oscillators in the rat suprachiasmatic nucleus in vitro. Proc Natl Acad Sci USA 1995;92:7396-7400.

129. Shuttleworth CW, Keef KD. Roles of peptides in enteric neuromuscular transmission. Regul Pept 1995;56:101-120.

130. Sirinek LP, O'Dorisio MS. Modulation of immune function by intestinal neuropeptides. Acta Oncol 1991;30:509-517.

131. Skakkebaek ML, Georg B, Mikkelsen JD, Ottesen B, Fahrenkrug J. All prepro-VIP-derived peptides, except PHI/PHV, are expressed in the female rat anterior pituitary and increased by estrogen. Peptides 1995;16:1287-1294.

132. Sloviter RS. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987;235:73-76.

133. Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci USA 1995;92:2939-2943.

134. Sun Y, Landis SC, Zigmond RE. Signals triggering the induction of leukemia inhibitory factor in sympathetic superior cervical ganglia and their nerve trunks after axonal injury. Mol Cell Neurosci 1996;7:152-163.

135. Sun Y, Rao MS, Zigmond RE, Landis SC. Regulation of vasoactive intestinal peptide expression in sympathetic neurons in culture and after axotomy: the role of cholinergic differentiation factor/leukemia inhibitory factor. J Neurobiol 1994;25:415-430.

136. Takashima A, Maeda Y, Itoh S. Influence of chronic intracerebroventricular infusion of vasoactive intestinal peptide (VIP) on memory processes in Morris water pool test in the rat. Peptides 1993;14:1073-1078.

137. Talbot RT, Dunn IC, Wilson PW, Sang HM, Sharp PJ. Evidence for alternative splicing of the chicken vasoactive intestinal polypeptide gene transcript. J Mol Endocrinol 1995;15:81-91.

138. Tanaka S, Koike T. Vasoactive intestinal peptide suppresses neuronal cell death induced by nerve growth factor deprivation in rat sympathetic ganglion cells in vitro. Neuropeptides 1994;26:103-111.

139. Taylor AD, Cowell AM, Flower RJ, Buckingham JC. Dexamethasone suppresses the release of prolactin from the rat anterior pituitary gland by lipocortin 1 dependent and independent mechanisms. Neuroendocrinology 1995;62:530-542.

140. Tolentino PJ, Dikkes P, Tsuruda L, et al. Quantitative analysis of the expression of a VIP transgene. Brain Res Mol Brain Res 1995;33:47-60.

141. Tyrrell S, Landis SC. The appearance of NPY and VIP in sympathetic neuroblasts and subsequent alterations in their expression. J Neurosci 1994;14:4529-4547.

142. Ugrumov MV, Trembleau A, Calas A. Altered vasoactive intestinal polypeptide gene expression in the fetal rat suprachiasmatic nucleus following prenatal serotonin deficiency. Int J Dev Neurosci 1994;12:143-149.

143. Unsicker K, Stogbauer F. Screening of adrenal medullary neuropeptides for putative neurotrophic effects. Int J Dev Neurosci 1992;10:171-179.

144. Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994;135:2662-2680.

145. Verge VM, Richardson PM, Wiesenfeld-Hallin Z, Hokfelt T. Differential influence of nerve growth factor on neuropeptide expression in vivo: a novel role in peptide suppression in adult sensory neurons. J Neurosci 1995;15:2081-2096.

146. Vincent MB. Cyclooxygenase inhibitors modify the relaxant effect of vasoactive intestinal polypeptide and substance P in isolated porcine ophthalmic artery. Cephalalgia 1992;12:15-19.

147. Vincent MB, White LR, Bakken IJ, Sjaastad O. Sumatriptan relaxes isolated porcine ophthalmic artery, but inhibits VIP-induced relaxation. Cephalalgia 1993;13:378-382; discussion 375.

148. Wahle P, Meyer G. Early postnatal development of vasoactive intestinal polypeptide-and peptide histidine isoleucine-immunoreactive structures in the cat visual cortex. J Comp Neurol 1989;282:215-248.

149. Wang YY, Aghajanian GK. Excitation of locus coeruleus neurons by vasoactive intestinal peptide: role of a cAMP and protein kinase A. J Neurosci 1990;10:3335-3343.

150. Waschek JA. Vasoactive intestinal peptide: an important trophic factor and developmental regulator. Dev Neurosci 1995;171-177.

151. Waschek JA, Ellison J, Bravo DT, Handley V. Embryonic expression of vasoactive intestinal peptide (VIP) and VIP receptor genes. J Neurochem 1996;66:1762-1765.

152. Waschek JA, Muller JM, Duan DS, Sadee W. Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell, SH-SY5Y. FEBS Lett 1989;250:611-614.

153. Watanobe H, Tamura T. Stimulation by peptide histidine methionine (PHM) of adrenocorticotropin secretion in patients with Cushing's disease: a comparison with the effect of vasoactive intestinal peptide (VIP) and a study on the effect of combined administration of corticotropin-releasing hormone with PHM or VIP. J Clin Endocrinol Metab 1994;78:1372-1377.

154. Weick RF, Stobie KM. Role of VIP in the regulation of LH secretion in the female rat. Neurosci Biobehav Rev 1995;19:251-259.

155. Wolford JK, Signs SA. Binding of sequence-specific proteins to the 3'-untranslated region of vasoactive intestinal peptide mRNA. Biochem Biophys Res Commun 1995;211:819-825.

156. Wollman Y, Lilling G, Goldstein MN, Fridkin M, Gozes I. Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells. Brain Res 1993;624:339-341.

157. Yamaguchi Y, Kobayashi H. Effects of vasoactive intestinal peptide (VIP) on scopolamine-induced amnesia in the rat. Neuropeptides 1994;26:153-158.

158. Yashpal K, Sarrieau A, Quirion R. [125I]vasoactive intestinal polypeptide binding sites: quantitative autoradiographic distribution in the rat spinal cord. J Chem Neuroanat 1991;4:439-446.

159. You S, Silsby JL, Farris J, Foster DN, el Halawani ME. Tissue-specific alternative splicing of turkey preprovasoactive intestinal peptide messenger ribonucleic acid, its regulation, and correlation with prolactin secretion. Endocrinology 1995;136:2602-2610.

160. Zhang QL, Lin PX, Shi D, Xian H, Webster HD. Vasoactive intestinal peptide: mediator of laminin synthesis in cultured Schwann cells. J Neurosci Res 1996;43:496-502.

161. Zhou JN, Hofman MA, Swaab DF. VIP neurons in the human SCN in relation to sex, age, and Alzheimer's disease. Neurobiol Aging 1995;16:571-576.